Quanterix Corporation announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category.
The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide.
The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa technology to deliver precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation.
Accelerator’s Simoa NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu.
Additionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab’s rigor and ultra-sensitive Simoa technology with Lucent Diagnostics’ focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics.
To learn more about the Quanterix Accelerator Laboratory, visit: https://www.quanterix.com/products-and-services/pharma-services/.
Read Quanterix's announcement on Businesswire
